Black, Jonathan <br/><br/>
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.  [electronic resource] 

 -  Molecular cancer therapeutics  08 2016 
 - 1900-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-16-0163  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Antibody-Dependent Cell Cytotoxicity--immunology<br/>Antineoplastic Agents--chemistry<br/>Bystander Effect<br/>Cathepsin B--genetics<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Class I Phosphatidylinositol 3-Kinases<br/>Cystadenocarcinoma, Serous--drug therapy<br/>Disease Models, Animal<br/>Duocarmycins<br/>Female<br/>Gene Expression<br/>Humans<br/>Immunoconjugates--chemistry<br/>Indoles--chemistry<br/>Mice<br/>Middle Aged<br/>Mutation<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Pyrrolidinones--chemistry<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Survival Analysis<br/>Uterine Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays